药理性甲酸盐和DNMT抑制剂在胰腺癌中增加DUOX表达和过氧化物中介毒性
Garett J Steers1,2, Brianne R O'Leary1,2, Juan Du1,2
1Free Radical and Radiation Biology Division, Department of Radiation Oncology, Iowa City, IA 52242, USA.
Antioxidants (Basel, Switzerland)
|September 28, 2023
概括
高剂量的维生素C和DNA甲基转移酶抑制剂在胰腺癌中增加双氧化酶表达. 这种组合疗法增加了细胞死亡,这表明胰腺管道腺癌的新型表观遗传治疗策略.
科学领域:
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 癌症生物学 癌症生物学
- 营养生物化学 营养生物化学
背景情况:
- 维生素C (酸) 通过通过十一转位 (TET) 酶通过DNA脱甲基化影响与癌症相关的基因表达.
- DNA甲基转移酶 (DNMT) 酶通过增加DNA甲基化和抑制基因表达来抵消TET活性.
- 对于过氧化产生至关重要的双氧化酶 (DUOX) 在胰腺管道腺癌 (PDAC) 中被静止.
研究的目的:
- 为了研究药理性甲酸盐 (P-AscH-) 和DNMT抑制剂对PDAC中的DUOX表达的协同作用.
- 在PDAC模型中评估这种联合治疗对细胞内氧化和细胞毒性的影响.
主要方法:
- 用DNMT抑制剂对PDAC细胞进行治疗,以评估DUOX mRNA和蛋白质表达.
- 使用P-AscH和DNMT抑制剂的组合疗法在体外和体内的PDAC细胞中被施用.
- 测量包括DUOX表达,细胞内氧化水平和细胞活力.
主要成果:
- 单独使用DNMT抑制剂就会诱导PDAC细胞中DUOX表达的剂量依赖性增加.
- 与单一治疗相比,P-AscH和DNMT抑制剂的组合显著增强了DUOX表达.
- 联合治疗导致细胞内氧化升高,在体外和体内PDAC模型中增加细胞毒性.
结论:
- 抑制DNMT与药理性甲酸盐协同作用,在胰腺癌中调高DUOX表达.
- 这种表观遗传方法增加了氧化应激,并增强了维生素C在PDAC中的抗癌作用.
- P-AscH和DNMT抑制的组合为胰腺癌治疗提供了一个有前途的治疗策略.
相关概念视频
Electron Transport Chain: Complex I and II
14.3K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
14.3K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


